Hormonal
GLP-1-based peptide therapeutics achieve 15–25% body weight loss with once-weekly dosing, surpassing the efficacy of previous small-molecule drugs and matching bariatric surgery outcomes.
GLP-1 therapies like semaglutide and tirzepatide offer a powerful medical option for obesity, achieving 15-25% weight loss with once-weekly injections. This efficacy rivals bariatric surgery but without the surgical risks. However, these drugs require ongoing use to maintain results, and access can be limited by cost and supply. Consult a healthcare provider to determine if this treatment is appropriate for your specific health profile.
By harnessing the body’s natural peptide hormonal mechanisms, these GLP-1-based therapies have achieved loss of 15–25%, once thought impossible, while also demonstrating excellent safety. Such weight loss levels were previously believed to be only achievable through bariatric surgery
Why this rating
Based on multiple Phase 3 clinical trials and FDA approvals cited in the review.
Source
Advancing obesity treatments through innovations in the design and manufacturing of therapeutic peptides
Søren Østergaard · Expert Opinion on Drug Discovery · 2025
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →